269 related articles for article (PubMed ID: 9554884)
41. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis.
Grantham JA; Schirger JA; Wennberg PW; Sandberg S; Heublein DM; Subkowski T; Burnett JC
Circulation; 2000 Apr; 101(16):1976-81. PubMed ID: 10779465
[TBL] [Abstract][Full Text] [Related]
42. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
Trapani AJ; Beil ME; Bruseo CW; Savage P; Firooznia F; Jeng AY
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S211-5. PubMed ID: 15838282
[TBL] [Abstract][Full Text] [Related]
43. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines.
Usmani BA; Harden B; Maitland NJ; Turner AJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():314S-317S. PubMed ID: 12193112
[TBL] [Abstract][Full Text] [Related]
44. Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin.
Hoang MV; Turner AJ
Biochem J; 1997 Oct; 327 ( Pt 1)(Pt 1):23-6. PubMed ID: 9355729
[TBL] [Abstract][Full Text] [Related]
45. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle.
Maguire JJ; Johnson CM; Mockridge JW; Davenport AP
Br J Pharmacol; 1997 Dec; 122(8):1647-54. PubMed ID: 9422810
[TBL] [Abstract][Full Text] [Related]
46. Development of an internally quenched fluorescent substrate selective for endothelin-converting enzyme-1.
Johnson GD; Ahn K
Anal Biochem; 2000 Nov; 286(1):112-8. PubMed ID: 11038281
[TBL] [Abstract][Full Text] [Related]
47. Pressor and pulmonary responses to ET-1(1-31) in guinea-pigs.
Honoré JC; Plante M; Bkaily G; Rae GA; D'Orléans-Juste P
Br J Pharmacol; 2002 Jul; 136(6):819-28. PubMed ID: 12110606
[TBL] [Abstract][Full Text] [Related]
48. Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease.
Kuruppu S; Rajapakse NW; Smith AI
Pflugers Arch; 2013 Jul; 465(7):929-34. PubMed ID: 23328864
[TBL] [Abstract][Full Text] [Related]
49. Effects of a selective neutral endopeptidase and a nonselective neutral endopeptidase/endothelin-converting enzyme inhibitor on lipopolysaccharide-induced endotoxaemia in anaesthetized Sprague-Dawley rats.
Pham D; Jeng AY; Escher E; Sirois P; Battistini B
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S362-6. PubMed ID: 11078421
[TBL] [Abstract][Full Text] [Related]
50. Sustained improvement of cardiac function and prevention of cardiac remodeling after long-term dual ECE-NEP inhibition in rats with congestive heart failure.
Mulder P; Barbier S; Monteil C; Jeng AY; Henry JP; Renet S; Thuillez C
J Cardiovasc Pharmacol; 2004 Apr; 43(4):489-94. PubMed ID: 15085059
[TBL] [Abstract][Full Text] [Related]
51. Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage.
Sharkovska Y; Kalk P; von Websky K; Relle K; Pfab T; Alter M; Fischer Y; Hocher B
Clin Lab; 2011; 57(7-8):507-15. PubMed ID: 21888014
[TBL] [Abstract][Full Text] [Related]
52. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure.
Dickstein K; De Voogd HJ; Miric MP; Willenbrock R; Mitrovic V; Pacher R; Koopman PA
Am J Cardiol; 2004 Jul; 94(2):237-9. PubMed ID: 15246912
[TBL] [Abstract][Full Text] [Related]
53. [Phe21]big endothelin-1(18-34) and [Ala31]big endothelin-1(18-34) inhibit the human endothelin-converting enzyme-1 (ECE-1) expressed in CHO-K1 cells in a different fashion.
Liu W; Takayanagi R; Ito T; Oba K; Nawata H
FEBS Lett; 1997 Dec; 420(1):103-6. PubMed ID: 9450558
[TBL] [Abstract][Full Text] [Related]
54. Endothelin-converting enzyme inhibitors: current status and perspectives.
Löffler BM
J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S79-82. PubMed ID: 10976788
[TBL] [Abstract][Full Text] [Related]
55. Hydrolysis of peptide hormones by endothelin-converting enzyme-1. A comparison with neprilysin.
Johnson GD; Stevenson T; Ahn K
J Biol Chem; 1999 Feb; 274(7):4053-8. PubMed ID: 9933597
[TBL] [Abstract][Full Text] [Related]
56. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer.
Smollich M; Götte M; Yip GW; Yong ES; Kersting C; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Breast Cancer Res Treat; 2007 Dec; 106(3):361-9. PubMed ID: 17295044
[TBL] [Abstract][Full Text] [Related]
57. Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme identified in rat lung.
Shiosaki K; Tasker AS; Sullivan GM; Sorensen BK; von Geldern TW; Wu-Wong JR; Marselle CA; Opgenorth TJ
J Med Chem; 1993 Feb; 36(4):468-78. PubMed ID: 8474103
[TBL] [Abstract][Full Text] [Related]
58. In vivo role of endothelin-converting enzyme-1 as examined by adenovirus-mediated overexpression in rats.
Télémaque S; Emoto N; deWit D; Yanagisawa M
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S548-50. PubMed ID: 9595539
[TBL] [Abstract][Full Text] [Related]
59. S 17162 is a novel selective inhibitor of big ET-1 responses in the rat.
Descombes JJ; Mennecier P; Versluys D; Barou V; de Nanteuil G; Laubie M; Verbeuren TJ
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S61-4. PubMed ID: 8587469
[TBL] [Abstract][Full Text] [Related]
60. [Phe22]-big endothelin-1[19-37]: a new and potent inhibitor of the endothelin-converting enzyme.
Claing A; Neugebauer W; Yano M; Rae GA; D'Orléans-Juste P
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S72-4. PubMed ID: 8587472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
